Company Filing History:
Years Active: 1992-2001
Title: Kenneth M Attie: Innovator in Growth Hormone Treatments
Introduction
Kenneth M Attie is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of medicine, particularly in the treatment of growth hormone insensitivity syndromes. With a total of 4 patents to his name, Attie's work has the potential to improve the lives of many patients.
Latest Patents
One of Kenneth M Attie's latest patents focuses on the treatment of partial growth hormone insensitivity syndrome. This patent describes methods for increasing the growth rate of human patients who have this condition, but not Laron syndrome. One method involves administering an effective dose of growth hormone, preferably with a native human sequence, to patients characterized by specific serum levels and height measurements. Another method includes treating the same patient population with an effective amount of IGF-I, either alone or in combination with growth hormone.
Career Highlights
Attie is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to medicine. His work at Genentech has allowed him to focus on developing treatments that address critical health issues related to growth hormone deficiencies.
Collaborations
Throughout his career, Kenneth M Attie has collaborated with esteemed colleagues such as Neil Gesundheit and Audrey Goddard. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Kenneth M Attie's contributions to the field of growth hormone treatments exemplify the impact of innovative thinking in medicine. His patents and ongoing work continue to pave the way for advancements that can significantly benefit patients with growth hormone insensitivity syndromes.